Pre-Made Oreptacog Alfa Biosimilar, Recombinant Protein targeting F7: Recombinant therapeutic protein targeting SPCA for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-941

Pre-Made Oreptacog Alfa Biosimilar, Recombinant Protein targeting F7: Recombinant therapeutic protein targeting SPCA is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eptacog alfa，also known as recombinant activated factor VII, is a recombinant factor VIIa for the treatment of bleeding episodes in patients with acquired haemophilia.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-941-1mg 1mg 3090
GMP-Bios-INN-941-10mg 10mg Inquiry
GMP-Bios-INN-941-100mg 100mg Inquiry
GMP-Bios-INN-941-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Oreptacog Alfa Biosimilar, Recombinant Protein targeting F7: Recombinant therapeutic protein targeting SPCA
INN Name Oreptacog Alfa
TargetF7
FormatRecombinant Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeF7 (coagulation factor VII, coagulation serum prothrombin conversion accelerator)
VD LCF7 (coagulation factor VII, coagulation serum prothrombin conversion accelerator)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesBayer HealthCare Pharmaceuticals (Leverkusen Germany)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0